Prescription medicine
Ascorbic acid, polyethylene glycol 3350 and 4 other ingredients Brand names: Plenvu, Moviprep
Ascorbic acid, polyethylene glycol 3350 and 4 other ingredients (Plenvu) is a prescription medicine with an FDA approval on record since 2006. No generic is listed in FDA's NDC Directory.
- No generic listed
- A presentation discontinued
Check it at the source: the ascorbic acid, polyethylene glycol 3350 and 4 other ingredients FDA label on DailyMed (effective October 31, 2025, Salix Pharmaceuticals, Inc.); the NDA 21881 record on Drugs@FDA; every ascorbic acid, polyethylene glycol 3350 and 4 other ingredients label on DailyMed.
Highlights of the record
FDA label of October 31, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageMoviPrep® is an osmotic laxative indicated for cleansing of the colon as a preparation for colonoscopy in adults.
Forms and strengths
Kit.
On the market
- Earliest approval on file
- August 2, 2006 Moviprep, Salix Pharms; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 2 first January 25, 2012; 1 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 3 of which 0 under generic applications, 3 under brand applications, repackagers included
- Last listed patent
- September 10, 2033 Plenvu for solution; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- None current 1 past records
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 3,195 through July 30, 2026
What is ascorbic acid, polyethylene glycol 3350 and 4 other ingredients used for?
From the label: indications and usageMoviPrep® is an osmotic laxative indicated for cleansing of the colon as a preparation for colonoscopy in adults. MoviPrep is an osmotic laxative indicated for cleansing of the colon as a preparation for colonoscopy in adults.
Source: FDA drug label (MoviPrep), Salix Pharmaceuticals, Inc., effective October 31, 2025 (SPL set 8ff46193-2a3b-4de0-9572-775dda8cd8b2), via openFDA; the full label on DailyMed
What does the patient leaflet for ascorbic acid, polyethylene glycol 3350 and 4 other ingredients say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about MoviPrep?MoviPrep and other bowel preparations can cause serious side effects, including: • Serious loss of body fluid (dehydration) and changes in blood salts (electrolytes) in your blood. These changes can cause: o abnormal heartbeats that can cause death. o seizures. This can happen even if you have never had a seizure. o kidney problems. Your chance of having fluid loss and changes in body salts with MoviPrep is higher if you: • have heart problems. • have kidney problems. • take water pills (diuretics), high blood pressure medicine, or non-steroidal anti-inflammatory drugs (NSAIDs). Tell your healthcare provider right away if you have any of these symptoms of serious loss of body fluid (dehydration) while taking MoviPrep: • vomiting • urinating less often than normal • dizziness • headache See “What are the possible side effects of MoviPrep?” for more information about side effects.
From the patient leaflet: How should I store MoviPrep?Store MoviPrep that has not been mixed with water at room temperature, between 68°F to 77°F (20°C to 25°C). • Store MoviPrep that has been mixed with water in an upright position in the refrigerator. • MoviPrep should be taken within 24 hours after it has been mixed with water. Keep MoviPrep and all medicines out of the reach of children.
Source: FDA drug label (MoviPrep), Salix Pharmaceuticals, Inc., effective October 31, 2025 (SPL set 8ff46193-2a3b-4de0-9572-775dda8cd8b2), via openFDA; the full label on DailyMed
Is there a generic for ascorbic acid, polyethylene glycol 3350 and 4 other ingredients (Plenvu)?
The FDA approved the first generic ascorbic acid, polyethylene glycol 3350 and 4 other ingredients on January 25, 2012. 2 generic applications are approved; 1 of them carries a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
The Orange Book lists 11 patents for Plenvu for solution, the last expiring on September 10, 2033. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2006 earliest approval on file
- 2012 first generic approved
- 2033 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
Is ascorbic acid, polyethylene glycol 3350 and 4 other ingredients in shortage?
No ascorbic acid, polyethylene glycol 3350 and 4 other ingredients presentation is listed as in shortage in the FDA Drug Shortage Database (read October 8, 2026); its 1 record is all marked to be discontinued, the latest updated August 13, 2026. ASHP keeps a separate shortage list, which can differ.
| Presentation | Company | Status | Updated |
|---|---|---|---|
| Plenvu, Oral Solution, KIT (NDC 65649-400-01) | Salix Pharmaceuticals, a division of Bausch Health US, LLC | To Be Discontinued | August 13, 2026 |
Source: FDA Drug Shortage Database via openFDA, updated October 8, 2026
What does the ascorbic acid, polyethylene glycol 3350 and 4 other ingredients label say about other medicines?
The ascorbic acid, polyethylene glycol 3350 and 4 other ingredients label names 1 other medicine in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Bisacodyl | drug interactions | Avoid use of stimulant laxatives (e.g., bisacodyl, sodium picosulfate) while taking MoviPrep [see Warnings and Precautions ( 5.5 , 5.6 )]. |
Check ascorbic acid, polyethylene glycol 3350 and 4 other ingredients against other medicines
Source: FDA drug label (MoviPrep), Salix Pharmaceuticals, Inc., effective October 31, 2025 (SPL set 8ff46193-2a3b-4de0-9572-775dda8cd8b2), via openFDA; the full label on DailyMed
What do FAERS reports show for ascorbic acid, polyethylene glycol 3350 and 4 other ingredients?
The FDA Adverse Event Reporting System holds 3,195 reports that list ascorbic acid, polyethylene glycol 3350 and 4 other ingredients among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 263 are coded as a death and 1,123 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Ascorbic acid, polyethylene glycol 3350 and 4 other ingredients side effects
- the label's list beside FAERS reports
- Ascorbic acid, polyethylene glycol 3350 and 4 other ingredients shortage record
- every presentation, company and date
- Check an interaction
- what two or more labels say about each other